Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPI | P09923 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.61 |
| ▸ | XIAP | P98170 | 1/20 | 0.61 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.61 |
| ▸ | SLC15A1 | P46059 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.49 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.49 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.47 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13087400 | 1.00 | ALPI (0.61) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL5547318 | 1.00 | ALPI (0.61) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL8835936 | 0.91 | SLC7A5 (0.68) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL288607 | 0.91 | SLC7A5 (0.68) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL28820471 | 0.91 | SLC7A5 (0.68) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL29160724 | 0.89 | SLC7A5 (0.66) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL10914203 | 0.88 | FFAR1 (0.50) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL8609126 | 0.87 | SLC7A5 (0.63) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL1526409 | 0.87 | ALPI (0.63) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL27232046 | 0.87 | ALPI (0.63) | ALPIPKMPTGS1XIAPSLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 796 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3337456-B1 | LIPOSOMES WITH GINSENOSIDE AS MEMBRANE MATERIAL AND PREPARATIONS AND USE THEREOF | SHANGHAI GINPOSOME PHARMATECH CO LTD (CN) | 2022-10-26 | — | — | EP | claimed |
| EP-3773910-A1 | HUMANIZED ANTI-PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) ANTIBODY DRUG CONJUGATES | Ambrx, Inc. (US) | 2021-02-17 | — | — | EP | claimed |
| US-10639276-B2 | Liposomes with ginsenoside as membrane material and preparations and use thereof | SHANGHAI GINPOSOME PHARMATECH CO., LTD. (CN) | 2020-05-05 | — | — | US | claimed |
| CN-110885404-A | Synthesis method of active bagasse xylan acetyl phenylalanine ester-g-VAc | 桂林理工大学 | 2020-03-17 | — | — | CN | claimed |
| WO-2019191728-A1 | HUMANIZED ANTI-PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) ANTIBODY DRUG CONJUGATES | AMBRX, INC. (US) | 2019-10-03 | — | — | WO | claimed |
| EP-3463415-A1 | AQUEOUSLY SOLUBLE & CHEMICALLY STABLE GLUCAGON PEPTIDES | Indiana University Research & Technology Corporation (US) | 2019-04-10 | — | — | EP | claimed |
| EP-3463423-A1 | GLUCAGON-T3 CONJUGATES | Indiana University Research & Technology Corporation (US) | 2019-04-10 | — | — | EP | claimed |
| US-10232020-B2 | Incretin-insulin conjugates | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2019-03-19 | — | — | US | claimed |
| EP-3337456-A1 | LIPOSOMES WITH GINSENOSIDE AS MEMBRANE MATERIAL AND PREPARATIONS AND USE THEREOF | Shanghai Ginposome Pharmatech Co., Ltd. (CN) | 2018-06-27 | — | — | EP | claimed |
| EP-2780031-B1 | GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING GLUCOCORTICOID RECEPTOR ACTIVITY | UNIV INDIANA RES & TECH CORP (US) | 2018-03-07 | — | — | EP | claimed |
| EP-1836298-A4 | COMPOSITIONS OF AMINOACYL-tRNA SYNTHETASE AND USES THEREOF | AMBRX INC (US) | 2008-07-09 | — | — | EP | claimed |
| EP-1937824-A1 | COMPOSITIONS OF tRNA AND USES THEREOF | Ambrx, Inc. (US) | 2008-07-02 | — | — | EP | claimed |
| EP-1836298-A2 | COMPOSITIONS OF AMINOACYL-tRNA SYNTHETASE AND USES THEREOF | AMBRX, INC. (US) | 2007-09-26 | — | — | EP | claimed |
| WO-2007021297-A1 | COMPOSITIONS OF tRNA AND USES THEREOF | AMBRX, INC. (US) | 2007-02-22 | — | — | WO | claimed |
| WO-2006068802-A2 | COMPOSITIONS OF AMINOACYL-tRNA SYNTHETASE AND USES THEREOF | AMBRX, INC. (US) | 2006-06-29 | — | — | WO | claimed |
| US-5688913-A | OLIGOPEPTIDES AS ANTIINFLAMMATORY AGENTS | CYTEL CORPORATION (US) | 1997-11-18 | — | — | US | claimed |
| US-5519000-A | OLIGOPEPTIDE | CENTECOR, INC. (US) | 1996-05-21 | — | — | US | claimed |
| WO-1995026744-A1 | TUMOR NECROSIS FACTOR INHIBITORS | CENTOCOR, INC. (US) | 1995-10-12 | — | — | WO | claimed |
| CN-1091952-A | Cosmetic composition | UNILEVER NV (NL) | 1994-09-14 | — | — | CN | claimed |
| EP-0203031-B1 | BIOLOGICALLY ACTIVE LYSINE CONTAINING OCTAPEPTIDES | The Administrators of The Tulane University Educational Fund (US) | 1992-07-29 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10639276-B2 | Liposomes with ginsenoside as membrane material and preparations and use thereof | SGMS1, LIPA, SGMS2 | ALPI 1642/4885PKM 2634/4885PTGS1 222/4885 |
| US-10232020-B2 | Incretin-insulin conjugates | GPR119, GLP1R, GIPR | ALPI 571/4885PKM 4013/4885PTGS1 3983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.